Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01996527 · ClinicalTrials.gov registry record · Early Phase 1

3T MRI Biomarkers of Glioma Treatment Response

A Early Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.

Terminated
Registry status
Early Phase 1
Development phase
7
Enrollment target

NCT01996527: Clinical Trial Early Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.

NCT01996527 is a Early Phase 1 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 7 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01996527, a Early Phase 1 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.

TERMINATED
Registry status
Early Phase 1
Development phase
7 participants
Enrollment target

Study Summary

This pilot clinical trial studies advanced magnetic resonance imaging (MRI) techniques in measuring treatment response in patients with high-grade glioma. New diagnostic procedures, such as advanced MRI techniques at 3 Tesla, may be more effective than standard MRI in measuring treatment response in patients receiving treatment for high-grade gliomas.

Primary Outcome

Number of patients in each response category, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, summarized as follows for target lesion criteria: complete response (CR),disappearance of target lesions; partial response (PR), \>=30% decrease in sum of longest diameter (LD) of target lesions; progressive disease (PD), \>=20% increase in sum of LD of target lesions or appearance of new lesions; stable disease (SD), insufficient change in target lesions or new lesions to qualify as eit

Interventions

  • DEVICE DCE-MRI
  • DEVICE 3-Tesla magnetic resonance imaging
  • DEVICE CEST-MRI
  • DEVICE DW-MRI
  • DEVICE DSC-MRI

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2012-05
Est. Completion 2016-01-01
Phase Early Phase 1
Vanderbilt-Ingram Cancer Center

189 total trials

Why NCT01996527 stopped before completion

NCT01996527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower).

The record links to 0 conditions, and to 5 interventions - of which DCE-MRI is the first listed.

NCT01996527 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01996527 about?

NCT01996527 is a clinical study titled "3T MRI Biomarkers of Glioma Treatment Response". This pilot clinical trial studies advanced magnetic resonance imaging (MRI) techniques in measuring treatment response in patients with high-grade glioma. New diagnostic procedures, such as advanced MRI techniques at 3 Tesla, may be more effective than standard MRI in measuring treatment response in...

What is the current status of trial NCT01996527?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2012-05. Estimated completion is 2016-01-01.

What interventions are being tested in trial NCT01996527?

The interventions under investigation include: DCE-MRI (DEVICE), 3-Tesla magnetic resonance imaging (DEVICE), CEST-MRI (DEVICE), DW-MRI (DEVICE), DSC-MRI (DEVICE).

Who is sponsoring clinical trial NCT01996527?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01996527's enrollment target sits among peer trials

7 1825th of 2000 higher than 156 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01996527, the US trial registry maintained by the National Library of Medicine. NCT01996527 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.